Daiichi Sankyo (Germany)
In research, Daiichi Sankyo (Germany) stands highest in Medicine (#4,600 of 17,978 worldwide), Health Sciences (#6,196 of 20,462 worldwide) and Life Sciences (#8,285 of 14,347 worldwide), over all time.
- World rank, 2022–2025
- #19,453 of 28,054 · #13,485 all time
- Rank in Germany
- #763 of 1,178
- Research works
- 1.1k ▲ 9% vs 2013–17
- Citations
- 22k 19.8 per fractional work
- Top-10% rate
- 12.3% record average 16.5%
- Open access
- 63% world 28%
What is Daiichi Sankyo (Germany) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #4,600 of 17,978 | 14.7% | 384 | |
| Health SciencesDomain | #6,196 of 20,462 | 14.7% | 406 | |
| Life SciencesDomain | #8,285 of 14,347 | 8.4% | 383 | |
| Physical SciencesDomain | #15,784 of 21,541 | 6.1% | 255 | |
| Biochemistry, Genetics and Molecular BiologyField | #6,027 of 7,814 | 8.5% | 240 | |
| Molecular BiologySubfield | #4,621 of 4,961 | 8.2% | 158 | |
| ChemistryField | #3,285 of 3,369 | 4.8% | 130 |
Each strip is that field’s whole ranked pool, with the notch where Daiichi Sankyo (Germany) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 4.7×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 4.7×
- Economics, Econometrics and Finance 3.5×
- Immunology and Microbiology 3.2×
- Medicine 2.7×
- Biochemistry, Genetics and Molecular Biology 2.6×
- Nursing 1.3×
- Chemistry 0.8×
- Mathematics 0.8×
- Arts and Humanities 0.8×
- Neuroscience 0.6×
- Business, Management and Accounting 0.6×
- Decision Sciences 0.6×
- Chemical Engineering 0.4×
- Health Professions 0.4×
- Engineering 0.4×
- Environmental Science 0.3×
- Agricultural and Biological Sciences 0.3×
- Social Sciences 0.2×
- Psychology 0.2×
- Materials Science 0.1×
- Earth and Planetary Sciences 0.1×
- Computer Science 0.1×
- Physics and Astronomy 0.1×
Who are the top researchers at Daiichi Sankyo (Germany)?
Ranked on the composite score, TATSUO HANEISHI, Hiroshi Sakurai and Kazunori Fujimoto lead among researchers whose main affiliation is Daiichi Sankyo (Germany).
- 1 TATSUO HANEISHI Germany · #554,414 worldwide 89 citations · 17 works
- 2 Hiroshi Sakurai Germany · #751,268 worldwide 8 citations · 17 works
- 3 Kazunori Fujimoto Germany · #1,329,422 worldwide 25 citations · 15 works
- 4 Tetsufumi Koga Germany · #1,540,283 worldwide 10 citations · 15 works
- 5 Sunao Manabe Germany · #1,550,732 worldwide 19 citations · 21 works
- 6 Takashi Yamoto Germany · #1,556,938 worldwide 14 citations · 19 works
Which keywords describe research at Daiichi Sankyo (Germany)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Clinical Trials, Breast Cancer, Genetic Variants, Monoclonal Antibody, Targeted Therapy, Cardiovascular Disease Prevention and Statins.
- Palbociclib
- CDK4/6 Inhibitors
- Hypertension
- Cell Cycle Control
- Glycosylation
- Metastasis
- EGFR Mutations
- Stroke Prevention
- Immunotherapy
- Clinical Practice Guidelines
- Anticoagulant Therapy
- Biomarkers
- Health Utility Measures
- Inflammation
- LDL Cholesterol
- Cholesterol-lowering
- Targeted Therapy
- Monoclonal Antibody
- Quality of Life
- Clinical Trials
- Chemotherapy
- Breast Cancer
- Genetic Variants
- Cardiovascular Disease Prevention
- Statins
- HER2
- Trastuzumab
- Cost-effectiveness Analysis
- Prognostic Factors
- Metastatic Breast Cancer
- Catheter Ablation
- Guidelines
- Atrial Fibrillation
- ALK Inhibitors
- Treatment Guidelines
- Radiotherapy
- Monoclonal Antibodies
- Genomic Profiles
- Small-Cell Lung Cancer
- Molecular Subtypes
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy11▲ 14×15 topics
- Clinical Trials11▲ 14×8 topics
- Breast Cancer8▲ 29×7 topics
- Quality of Life7▲ 4.2×14 topics
- Genetic Variants6▲ 32×3 topics
- Monoclonal Antibody6▲ 99×2 topics
- Cardiovascular Disease Prevention6▲ 58×2 topics
- Targeted Therapy6▲ 23×4 topics
- Statins5▲ 65×2 topics
- Cholesterol-lowering5▲ 101×1 topic
- HER25▲ 159×1 topic
- LDL Cholesterol5▲ 132×1 topic
- Trastuzumab5▲ 100×1 topic
- Inflammation5▲ 2.1×34 topics
- Cost-effectiveness Analysis4▲ 42×1 topic
- Health Utility Measures4▲ 42×1 topic
- Prognostic Factors4▲ 8.2×6 topics
- Biomarkers4▲ 5.0×10 topics
- Metastatic Breast Cancer4▲ 60×2 topics
- Anticoagulant Therapy4▲ 26×4 topics
- Catheter Ablation4▲ 27×2 topics
- Clinical Practice Guidelines4▲ 6.0×9 topics
- Guidelines4▲ 6.9×6 topics
- Immunotherapy3▲ 4.3×10 topics
- Atrial Fibrillation3▲ 29×1 topic
- Stroke Prevention3▲ 23×1 topic
- ALK Inhibitors3▲ 41×1 topic
- EGFR Mutations3▲ 41×1 topic
- Treatment Guidelines3▲ 12×3 topics
- Metastasis3▲ 7.3×6 topics
- Radiotherapy3▲ 6.0×8 topics
- Glycosylation2▲ 19×2 topics
- Monoclonal Antibodies2▲ 23×3 topics
- Cell Cycle Control2▲ 66×2 topics
- Genomic Profiles2▲ 45×1 topic
- Hypertension2▲ 6.8×6 topics
- Small-Cell Lung Cancer2▲ 45×1 topic
- CDK4/6 Inhibitors2▲ 75×1 topic
- Molecular Subtypes2▲ 22×2 topics
- Palbociclib2▲ 75×1 topic
Which research topics does Daiichi Sankyo (Germany) publish most on?
By volume in 2022–2025: Lipoproteins and Cardiovascular Health, HER2/EGFR in Cancer Research, Health Systems, Economic Evaluations, Quality of Life and Atrial Fibrillation Management and Outcomes.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lipoproteins and Cardiovascular Health Surgery 5 works
- 2 HER2/EGFR in Cancer Research Oncology 5 works
- 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 4 works
- 4 Atrial Fibrillation Management and Outcomes Cardiology and Cardiovascular Medicine 3 works
- 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
- 6 Lung Cancer Research Studies Oncology 2 works
- 7 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
- 8 Pharmaceutical Economics and Policy Economics and Econometrics 2 works
- 9 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 10 Cancer Treatment and Pharmacology Oncology 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Daiichi Sankyo (Germany)'s research output changed?
Output in 2018–2022 was 9% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Munich
- Ludwig-Maximilians-Universität München
- Max Planck Society
- Technical University of Munich
- Siemens (Germany)
- München Klinik
- LMU Klinikum
- Munich University of Applied Sciences
- TUM Klinikum
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.